Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 5/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | GIPR | P48546 | 2/20 | 0.32 |
| ▸ | GCG | P01275 | 1/20 | 0.32 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4942765 | 0.92 | PIK3CD (0.54) | PIK3CDMPOCYSLTR1PKMGCGR | |
| SCHEMBL5214659 | 0.88 | PIK3CD (0.57) | PIK3CDMPOCYSLTR1PKMGCGR | |
| SCHEMBL5214629 | 0.88 | PIK3CD (0.51) | PIK3CDMPOCYSLTR1PKMGCGR | |
| SCHEMBL5744199 | 0.85 | MPO (0.57) | PIK3CDMPOCYSLTR1PKM | |
| SCHEMBL5797414 | 0.84 | PIK3CD (0.47) | PIK3CDMPOCYSLTR1PKMGCGR | |
| SCHEMBL5215803 | 0.84 | MPO (0.56) | PIK3CDMPOCYSLTR1PKMGCGR | |
| SCHEMBL4770049 | 0.81 | MPO (0.52) | PIK3CDMPOCYSLTR1PKM | |
| SCHEMBL5215860 | 0.80 | PIK3CD (0.44) | PIK3CDMPOCYSLTR1PKMGCGR | |
| SCHEMBL5215051 | 0.79 | PIK3CD (0.43) | PIK3CDMPOCYSLTR1PKMGCGR | |
| SCHEMBL5246136 | 0.79 | PIK3CD (0.51) | PIK3CDMPOCYSLTR1PKMGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636213-B1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER LAMBERT CO (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1636213-A1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | BRUENDL MICHELLE M (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108715-A1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | MALT1, CYP1B1, CYP4B1 | PIK3CD 3187/4885MPO 2020/4885CYSLTR1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.